KR20050082389A - 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 - Google Patents

직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 Download PDF

Info

Publication number
KR20050082389A
KR20050082389A KR1020040010835A KR20040010835A KR20050082389A KR 20050082389 A KR20050082389 A KR 20050082389A KR 1020040010835 A KR1020040010835 A KR 1020040010835A KR 20040010835 A KR20040010835 A KR 20040010835A KR 20050082389 A KR20050082389 A KR 20050082389A
Authority
KR
South Korea
Prior art keywords
ser
pro
leu
val
thr
Prior art date
Application number
KR1020040010835A
Other languages
English (en)
Korean (ko)
Inventor
정용훈
조훈식
박홍규
홍성희
이기완
Original Assignee
메덱스젠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메덱스젠 주식회사 filed Critical 메덱스젠 주식회사
Priority to KR1020040010835A priority Critical patent/KR20050082389A/ko
Priority to CNA2005800082091A priority patent/CN1942206A/zh
Priority to JP2006554029A priority patent/JP2007523158A/ja
Priority to AU2005203104A priority patent/AU2005203104B2/en
Priority to KR1020057011478A priority patent/KR100658050B1/ko
Priority to PCT/KR2005/000457 priority patent/WO2005077415A1/fr
Priority to CA002556739A priority patent/CA2556739A1/fr
Priority to US10/539,946 priority patent/US20070110746A1/en
Priority to BRPI0507216-6A priority patent/BRPI0507216A/pt
Priority to RU2006133911/13A priority patent/RU2342950C2/ru
Priority to EP05721863A priority patent/EP1615664A4/fr
Publication of KR20050082389A publication Critical patent/KR20050082389A/ko
Priority to ZA200606804A priority patent/ZA200606804B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J37/00—Baking; Roasting; Grilling; Frying
    • A47J37/04—Roasting apparatus with movably-mounted food supports or with movable heating implements; Spits
    • A47J37/049—Details of the food supports not specially adapted to one of the preceding types of food supports
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A22—BUTCHERING; MEAT TREATMENT; PROCESSING POULTRY OR FISH
    • A22C—PROCESSING MEAT, POULTRY, OR FISH
    • A22C17/00—Other devices for processing meat or bones
    • A22C17/006—Putting meat on skewers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
KR1020040010835A 2004-02-18 2004-02-18 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 KR20050082389A (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020040010835A KR20050082389A (ko) 2004-02-18 2004-02-18 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
PCT/KR2005/000457 WO2005077415A1 (fr) 2004-02-18 2005-02-18 Composition pharmaceutique utile dans le traitement de troubles immunologiques
JP2006554029A JP2007523158A (ja) 2004-02-18 2005-02-18 免疫疾患治療用の医薬組成物
AU2005203104A AU2005203104B2 (en) 2004-02-18 2005-02-18 Pharmaceutical composition for treatment of immunological disorders
KR1020057011478A KR100658050B1 (ko) 2004-02-18 2005-02-18 면역질환 치료용 약제학적 조성물
CNA2005800082091A CN1942206A (zh) 2004-02-18 2005-02-18 治疗免疫性疾病的药物组合物
CA002556739A CA2556739A1 (fr) 2004-02-18 2005-02-18 Composition pharmaceutique utile dans le traitement de troubles immunologiques
US10/539,946 US20070110746A1 (en) 2004-02-18 2005-02-18 Pharmaceutical composition for treatment of immunological disorders
BRPI0507216-6A BRPI0507216A (pt) 2004-02-18 2005-02-18 composição farmacêutica para tratamento de doenças imunológicas
RU2006133911/13A RU2342950C2 (ru) 2004-02-18 2005-02-18 Фармацевтическая композиция для лечения иммунологических заболеваний
EP05721863A EP1615664A4 (fr) 2004-02-18 2005-02-18 Composition pharmaceutique utile dans le traitement de troubles immunologiques
ZA200606804A ZA200606804B (en) 2004-02-18 2006-08-16 Pharmaceutical composition for treatment of immunological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040010835A KR20050082389A (ko) 2004-02-18 2004-02-18 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물

Publications (1)

Publication Number Publication Date
KR20050082389A true KR20050082389A (ko) 2005-08-23

Family

ID=34858737

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020040010835A KR20050082389A (ko) 2004-02-18 2004-02-18 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
KR1020057011478A KR100658050B1 (ko) 2004-02-18 2005-02-18 면역질환 치료용 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057011478A KR100658050B1 (ko) 2004-02-18 2005-02-18 면역질환 치료용 약제학적 조성물

Country Status (11)

Country Link
US (1) US20070110746A1 (fr)
EP (1) EP1615664A4 (fr)
JP (1) JP2007523158A (fr)
KR (2) KR20050082389A (fr)
CN (1) CN1942206A (fr)
AU (1) AU2005203104B2 (fr)
BR (1) BRPI0507216A (fr)
CA (1) CA2556739A1 (fr)
RU (1) RU2342950C2 (fr)
WO (1) WO2005077415A1 (fr)
ZA (1) ZA200606804B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145434A2 (fr) * 2008-03-31 2009-12-03 한화석유화학 주식회사 Cellules souches neuronales exprimant le cd70 pouvant inhiber les réactions immunitaires associées aux greffes et leurs utilisations

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20105059B (en) 2004-07-26 2010-08-10 Biogen Idec Inc Anti-cd154 antibodies
KR101301649B1 (ko) 2006-11-10 2013-08-30 삼성전자주식회사 기록/재생 방법, 기록/재생 장치 및 정보 저장 매체
BRPI0906903B8 (pt) * 2008-04-11 2021-05-25 Seattle Genetics Inc anticorpo monoclonal e método de detecção da expressão de cd70
EP2193790A1 (fr) 2008-12-04 2010-06-09 Klinikum der Universität Regensburg Inhibiteurs IL-3 à utiliser pour le traitement de l'arthrite rhumatoïde à un stade précoce
EP3929216A1 (fr) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2011068993A1 (fr) 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc
EP2718328A4 (fr) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
CN103045646B (zh) * 2012-12-27 2015-02-25 中国人民解放军军事医学科学院基础医学研究所 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
KR101640582B1 (ko) * 2014-05-09 2016-07-18 고려대학교 산학협력단 Ｌａｇ－3의 세포질 도메인을 포함하는 면역세포 표면에의 단백질 발현용 조성물 및 그의 이용
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics Inc molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
MX2018006823A (es) * 2015-12-21 2018-11-29 Brainon Inc Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva.
US11702458B2 (en) 2017-01-05 2023-07-18 Kahr Medical Ltd. PD1-41BBL fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
WO2018152687A1 (fr) * 2017-02-22 2018-08-30 I-Mab Anticorps dirigés contre le gène-3 d'activation des lymphocytes (lag-3) et leurs utilisations
CN110506059B (zh) 2017-04-05 2023-01-17 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4143214A1 (de) * 1991-07-25 1993-01-28 Boehringer Mannheim Gmbh Synergistisch wirkende antikoerperzusammensetzung
EP0607353A1 (fr) * 1991-10-07 1994-07-27 Biogen, Inc. Procede d'amelioration de la tolerance d'allogreffes ou de xenogreffes par administration d'une proteine de liaison de lfa-3 ou de cd2
JPH09510952A (ja) * 1993-10-06 1997-11-04 ザ ケネディー インスティチュート オブ リューマトロジー 自己免疫疾患および炎症性疾患の治療
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
EA003772B1 (ru) * 1996-11-29 2003-08-28 Апплайд Резеч Системз Арс Холдинг Н.В. Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
BR0110779A (pt) * 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2001275186A1 (en) * 2000-06-02 2001-12-17 Nicole Kirchhof Immunotherapeutic method to prevent islet cell rejection
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145434A2 (fr) * 2008-03-31 2009-12-03 한화석유화학 주식회사 Cellules souches neuronales exprimant le cd70 pouvant inhiber les réactions immunitaires associées aux greffes et leurs utilisations
WO2009145434A3 (fr) * 2008-03-31 2010-02-18 한화석유화학 주식회사 Cellules souches neuronales exprimant le cd70 pouvant inhiber les réactions immunitaires associées aux greffes et leurs utilisations

Also Published As

Publication number Publication date
AU2005203104A9 (en) 2005-09-01
BRPI0507216A (pt) 2007-06-19
ZA200606804B (en) 2008-04-30
WO2005077415A1 (fr) 2005-08-25
RU2006133911A (ru) 2008-03-27
EP1615664A4 (fr) 2006-12-27
AU2005203104B2 (en) 2006-11-16
JP2007523158A (ja) 2007-08-16
EP1615664A1 (fr) 2006-01-18
KR20060002740A (ko) 2006-01-09
RU2342950C2 (ru) 2009-01-10
CA2556739A1 (fr) 2005-08-25
US20070110746A1 (en) 2007-05-17
KR100658050B1 (ko) 2006-12-15
CN1942206A (zh) 2007-04-04
AU2005203104A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
KR20050082389A (ko) 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
KR100376544B1 (ko) 티(t)세포조절물질및방법
FI106044B (fi) Menetelmä nisäkkään interleukiini-4-reseptorin (IL-4R) ja sen vasta-aineen tuottamiseksi ja IL-4R:ä koodaava DNA, vektori ja isäntäsolu
US20020039577A1 (en) Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
US20030195338A1 (en) Concatameric immunoadhesion
HU211627A9 (en) Dna sequences, recombinant dna molecules and methods for obtaining lymphocyte function associated antigen-3
EP3121198B1 (fr) Dimère g-csf humain de recombinaison et son utilisation pour le traitement de maladies neurologiques
NO321707B1 (no) Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.
JP4219985B2 (ja) 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導
US20210299223A1 (en) Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor
HU226787B1 (en) A tumor necrosis factor related ligand
US5185441A (en) Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
CN111378625A (zh) 一种cxcl13趋化型car－t细胞的制备和应用
CN114641480A (zh) 作为pd-l1抑制剂和免疫调节剂用于治疗癌症和感染性疾病的大环肽
EP2737905B1 (fr) Utilisation d'un dimère g-csf dans la préparation d'un médicament pour le traitement de maladies neurodégénératives
EP4174088A1 (fr) Protéine de fusion comprenant un anticorps anti-lag-3 et il-2 et son utilisation
EP2692733B1 (fr) Acides nucléiques codant pour des formes solubles du CD83
KR102184377B1 (ko) 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
KR102256267B1 (ko) 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
EP4306545A1 (fr) Protéine de fusion du récepteur tnfr2 et april baff
AU2005209571A1 (en) Methods and compostions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI